Does the media prefer DNLI or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.33 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or ASND?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Denali Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Denali Therapeutics' score of 0.33 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or AXSM?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 2 mentions for Denali Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Denali Therapeutics' score of 0.33 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or DNLI?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Denali Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Denali Therapeutics' score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELAN or DNLI?

In the previous week, Elanco Animal Health had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 2 mentions for Denali Therapeutics. Elanco Animal Health's average media sentiment score of 0.88 beat Denali Therapeutics' score of 0.33 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Denali Therapeutics (DNLI) Competitors

$24.77 +0.72 (+2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$24.87 +0.10 (+0.42%)

As of 07:58 PM Eastern

Compare

DNLI vs. BEAM, ASND, AXSM, BBIO, and ELAN

Should you buy Denali Therapeutics stock or one of its competitors? MarketBeat compares Denali Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Denali Therapeutics include Beam Therapeutics (BEAM), Ascendis Pharma A/S (ASND), Axsome Therapeutics (AXSM), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Denali Therapeutics currently has a consensus price target of $34.25, indicating a potential upside of 38.27%. Beam Therapeutics has a consensus price target of $46.83, indicating a potential upside of 41.06%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.33 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Denali Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Denali Therapeutics (NASDAQ:DNLI) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Denali Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Denali Therapeutics' score of 0.33 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Denali Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Denali Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 38.27%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 23.81%. Given Denali Therapeutics' higher possible upside, research analysts plainly believe Denali Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A
Ascendis Pharma A/S	$814.57M	18.27	-$258M	$8.67	27.52

Ascendis Pharma A/S has a net margin of 57.87% compared to Denali Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Summary

Ascendis Pharma A/S beats Denali Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Axsome Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 2 mentions for Denali Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Denali Therapeutics' score of 0.33 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher revenue and earnings than Denali Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A
Axsome Therapeutics	$638.50M	19.50	-$183.17M	-$3.73	N/A

Denali Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 38.27%. Axsome Therapeutics has a consensus price target of $258.95, suggesting a potential upside of 7.02%. Given Denali Therapeutics' higher probable upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Denali Therapeutics' return on equity of -52.20% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Axsome Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Denali Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.77	-$724.93M	-$3.74	N/A
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Denali Therapeutics	N/A	-52.20%	-43.86%

BridgeBio Pharma presently has a consensus price target of $91.05, suggesting a potential upside of 32.66%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 38.27%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

In the previous week, BridgeBio Pharma had 11 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Denali Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Denali Therapeutics' score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Pharma beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Denali Therapeutics	N/A	-52.20%	-43.86%

Elanco Animal Health presently has a consensus price target of $28.55, suggesting a potential upside of 22.99%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 38.27%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

In the previous week, Elanco Animal Health had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 2 mentions for Denali Therapeutics. Elanco Animal Health's average media sentiment score of 0.88 beat Denali Therapeutics' score of 0.33 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has higher revenue and earnings than Denali Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.50	N/A
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A

Summary

Elanco Animal Health beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.82B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-8.60	11.07	21.07	22.20
Price / Sales	11.89	334.82	530.36	110.15
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.58	8.29	10.79	6.50
Net Income	-$512.54M	$23.85M	$3.56B	$336.88M
7 Day Performance	12.95%	5.21%	1.67%	-0.22%
1 Month Performance	32.89%	2.19%	0.43%	0.77%
1 Year Performance	81.86%	60.99%	32.84%	31.57%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.1701 of 5 stars	$24.77 +3.0%	$34.25 +38.3%	+73.1%	$3.82B	$330.53M	N/A	430	Analyst Forecast
BEAM Beam Therapeutics	3.2842 of 5 stars	$31.12 +7.2%	$46.83 +50.5%	+112.0%	$2.99B	$139.74M	N/A	510
ASND Ascendis Pharma A/S	4.9172 of 5 stars	$223.29 +2.4%	$295.39 +32.3%	+28.9%	$13.60B	$814.57M	25.75	1,189	Positive News Analyst Downgrade
AXSM Axsome Therapeutics	2.5181 of 5 stars	$253.40 -0.7%	$256.79 +1.3%	+146.2%	$13.13B	$638.50M	N/A	380	Positive News
BBIO BridgeBio Pharma	3.4915 of 5 stars	$68.00 +1.8%	$89.59 +31.8%	+65.2%	$13.08B	$502.08M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ASND, AXSM, BBIO, and ELAN

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Summary

How does Denali Therapeutics compare to BridgeBio Pharma?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ASND, AXSM, BBIO, and ELAN

How does Denali Therapeutics compare to Beam Therapeutics?

Which has more risk & volatility, DNLI or BEAM?

Do analysts rate DNLI or BEAM?

Which has stronger earnings and valuation, DNLI or BEAM?

Is DNLI or BEAM more profitable?

Do insiders & institutionals have more ownership in DNLI or BEAM?

Does the media prefer DNLI or BEAM?

Summary

How does Denali Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility & risk, DNLI or ASND?

Does the media prefer DNLI or ASND?

Do insiders and institutionals have more ownership in DNLI or ASND?

Do analysts rate DNLI or ASND?

Which has better valuation and earnings, DNLI or ASND?

Is DNLI or ASND more profitable?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Does the media refer more to DNLI or AXSM?

Which has stronger earnings & valuation, DNLI or AXSM?

Do analysts recommend DNLI or AXSM?

Do institutionals & insiders hold more shares of DNLI or AXSM?

Which has more risk & volatility, DNLI or AXSM?

Is DNLI or AXSM more profitable?

Summary

How does Denali Therapeutics compare to BridgeBio Pharma?

Which has better valuation & earnings, BBIO or DNLI?

Which has more volatility and risk, BBIO or DNLI?

Do insiders and institutionals hold more shares of BBIO or DNLI?

Is BBIO or DNLI more profitable?

Do analysts prefer BBIO or DNLI?

Does the media favor BBIO or DNLI?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Do institutionals and insiders hold more shares of ELAN or DNLI?

Which has more volatility & risk, ELAN or DNLI?

Is ELAN or DNLI more profitable?

Do analysts prefer ELAN or DNLI?

Does the media prefer ELAN or DNLI?

Which has better earnings & valuation, ELAN or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools